Cookies on this site

Oxford Cancer is delighted to announce the appointment of Professor Adam Mead as Director, joining Professors Mark Middleton and Tim Elliott in leading Oxford’s interdisciplinary cancer research community.

Professor Adam Mead

The expanded leadership team brings together internationally recognised expertise spanning clinical trials, immuno-oncology, translational science, and fundamental research, reflecting Oxford Cancer’s commitment to accelerating innovation from discovery science to patient benefit. 

Professor Adam Mead is Professor of Haematology at the University of Oxford, Consultant Haematologist at Oxford University Hospitals NHS Foundation Trust, and Deputy Director of the MRC Weatherall Institute of Molecular Medicine based at the Radcliffe Department of Medicine. His research focuses on understanding the genetic and cellular complexity of myeloproliferative neoplasms and related blood cancers, with the aim of developing more precise and effective treatments for patients.   

An internationally recognised clinician scientist, Professor Mead has led pioneering translational research programmes combining stem cell biology, genomics, and clinical trials to better understand how blood cancers develop, evolve, and respond to treatment. His appointment further strengthens Oxford Cancer’s breadth across solid tumour and haematological cancer research. 

Read the full story on the Oxford Cancer website.

Similar stories

Research shows for the first time that standard non-contrast CT scans can be analysed by AI to reveal hidden coronary inflammation

Researchers from 27 institutions across UK, USA, Europe and Australia, led by a team at the University of Oxford, have demonstrated how an AI technology can measure inflammation in the heart’s arteries using low-radiation CT heart scans typically used to measure calcium score.

Five European Research Council (ERC) Synergy Grants awarded to Oxford researchers for ambitious new collaborations

Five Oxford University academics are to co-lead ambitious new research projects backed by European Research Council (ERC) Synergy Grants, part of the EU’s Horizon Europe research and innovation programme. Synergy Grants support groups of two to four outstanding researchers who combine complementary expertise and resources to tackle ambitious scientific challenges that could not be addressed by individual teams alone.

Professor Ole Jensen (Department of Experimental Psychology) and colleagues received €13.6 million to discover when the brain is ready for language and social understanding

The team will use new wearable brain sensors to track cognitive development from before birth to eight years of age.

New 'molecular glue' helps break down antibiotic resistance enzymes in E. coli

Oxford University scientists have discovered a new approach to tackle antimicrobial resistance (AMR), using 'molecular glues' to encourage bacteria to destroy their own resistance-causing enzymes. The study has been published in Angewandte Chemie International Edition.

Stronger immune system may help protect against prostate cancer

Higher levels of proteins involved in activating and coordinating the immune system were associated with a lower risk of developing prostate cancer, in a new study led by researchers at the Nuffield Department of Population Health.

The Nuffield Department of Women's & Reproductive Health has published its Biennial Report 2024–26

The Biennial Report 2024–26 highlights two years of research excellence, innovation, collaboration and growth.